Literature DB >> 18451135

Subtypes of breast cancer show preferential site of relapse.

Marcel Smid1, Yixin Wang, Yi Zhang, Anieta M Sieuwerts, Jack Yu, Jan G M Klijn, John A Foekens, John W M Martens.   

Abstract

We explored whether the five previously reported molecular subtypes in breast cancer show a preference for organ-specific relapse and searched for molecular pathways involved. The "intrinsic" gene list describing the subtypes was used to classify 344 primary breast tumors of lymph node-negative patients. Fisher exact tests were used to determine the association between a tumor subtype and a particular site of distant relapse in these patients who only received local treatment. Modulated genes and pathways were identified in the various groups using Significance Analysis of Microarrays and Global Testing. Bone relapse patients were most abundant in the luminal subtypes but were found less than expected in the basal subtype. The reverse was true for lung and brain relapse patients with the remark that absence of lung relapse was luminal A specific. Finally, a pleura relapse, although rare, was found almost exclusively in both luminal subtypes. Many differentially expressed genes were identified, of which several were in common in a subtype and the site to which the subtype preferentially relapsed. WNT signaling was up-regulated in the basal subtype and in brain-specific relapse, and down-modulated in the luminal B subtype and in bone-specific relapse. Focal adhesion was found up-regulated in the luminal A subtype but down-regulated in lung relapse. The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site.

Entities:  

Mesh:

Year:  2008        PMID: 18451135     DOI: 10.1158/0008-5472.CAN-07-5644

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  331 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  MYC-induced apoptosis in mammary epithelial cells is associated with repression of lineage-specific gene signatures.

Authors:  Heidi M Haikala; Juha Klefström; Martin Eilers; Katrin E Wiese
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection.

Authors:  Kamran A Ahmed; William J Fulp; Anders E Berglund; Sarah E Hoffe; Thomas J Dilling; Steven A Eschrich; Ravi Shridhar; Javier F Torres-Roca
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-30       Impact factor: 7.038

4.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

5.  Tumour radiosensitivity is associated with immune activation in solid tumours.

Authors:  Tobin Strom; Louis B Harrison; Anna R Giuliano; Michael J Schell; Steven A Eschrich; Anders Berglund; William Fulp; Ram Thapa; Domenico Coppola; Sungjune Kim; Jessica Frakes; John Foekens; James J Mulé; Javier F Torres-Roca
Journal:  Eur J Cancer       Date:  2017-08-29       Impact factor: 9.162

6.  Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer.

Authors:  Rui-chao Zeng; Wei Zhang; Xing-qiang Yan; Zhi-qiang Ye; En-dong Chen; Du-ping Huang; Xiao-hua Zhang; Guan-li Huang
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

7.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

8.  Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

Authors:  Junhua Mai; Yi Huang; Chaofeng Mu; Guodong Zhang; Rong Xu; Xiaojing Guo; Xiaojun Xia; David E Volk; Ganesh L Lokesh; Varatharasa Thiviyanathan; David G Gorenstein; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

9.  Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.

Authors:  Fancy C Thomas; Kunal Taskar; Vinay Rudraraju; Satyanarayana Goda; Helen R Thorsheim; Julie A Gaasch; Rajendar K Mittapalli; Diane Palmieri; Patricia S Steeg; Paul R Lockman; Quentin R Smith
Journal:  Pharm Res       Date:  2009-09-23       Impact factor: 4.200

Review 10.  Epithelial to mesenchymal transition and breast cancer.

Authors:  Eva Tomaskovic-Crook; Erik W Thompson; Jean Paul Thiery
Journal:  Breast Cancer Res       Date:  2009-11-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.